Thyroid News and Research

RSS

New approach to drug design may yield more effective and less toxic cancer medicines

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.

16 Jun 2012

Invuity closes $25M Series D round of financing

Invuity, a leading developer of state-of-the-art surgical visualization and illumination technology, has raised a $25 million Series D round of financing to expand the development, manufacturing and commercialization of the company's advanced medical devices.

14 Jun 2012

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.

14 Jun 2012

Increased risk of brain aneurysm linked to early menopause

The younger a woman is when she goes through the menopause, the greater may be her risk of having a brain (cerebral) aneurysm, suggests research published online first in the Journal of NeuroInterventional Surgery.

12 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

HNC patients may be at increased risk for post-treatment side effects

New data from an Internet-based study show that patients with head and neck cancers (HNC) may be at risk for significant late effects after their treatment, but they're unlikely to discuss these and other survivorship care issues with their doctors.

2 Jun 2012

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Ventana Medical Systems, Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.

1 Jun 2012

Study shows how tafamidis drug works against amyloid disease

Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel) works.

31 May 2012

Exelixis files NDA with FDA for cabozantinib to treat MTC

Exelixis, Inc. today announced that it has completed the filing of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer.

30 May 2012

Nuclear radiation exposure more serious than previously believed

Recent news reports and scientific reviews warn that nuclear radiation exposure is more serious than we believed. Just recently, the UK Guardian published an article titled, "Fukushima reactor shows radiation levels much higher than thought."

25 May 2012

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

18 May 2012

Researchers discover protein that regulates activation of brown fat

Scientists have identified a protein which regulates the activation of brown fat in both the brain and the body's tissues. Their research, which was conducted in mice, was published today, Friday 11 May, in the journal Cell.

11 May 2012

Eye color linked to high-risk for skin conditions

Eye color may be an indicator of whether a person is high-risk for certain serious skin conditions. A study, led by the University of Colorado School of Medicine, shows people with blue eyes are less likely to have vitiligo.

7 May 2012

Growing role of body image drugs

In the current issue of Psychotherapy and Psychosomatics Kanayama et al. analyse the growing role of body image drugs.

4 May 2012

SPECT/CT can change clinical management of thyroid cancer

The use of single positron emission computed tomography (SPECT)/computed tomography (CT) has been reported to change clinical management in a significant number of thyroid cancer patients according to research presented in the May issue of The Journal of Nuclear Medicine.

4 May 2012

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Cervical spine CT examinations are unnecessary for emergency department (ED) patients who are a victim of "simple assault" or who have a "ground-level fall", unless the patient has a condition that predisposes the patient to spine fracture, a new study finds.

3 May 2012

HiLo trial sets new gold standard for thyroid cancer treatment

The results of a large Cancer Research UK trial have set a new gold standard for treating thyroid cancer, reducing radiation doses to just one third of the current level, according to research in The New England Journal of Medicine.

3 May 2012